Clinical trial registry record

Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 15, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03577041
Last registry update
June 15, 2026
Status
Recruiting
Phase
Phase not reported
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
600
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
600
Population
ALL · 18 Years to 70 Years
Duration
2020-01-29 to 2026-06-01
Intervention
Comparator
Not reported
Outcomes measured
Cost-utility analysis of the modalities of management of neovascular age-related macular degeneration — 12 months; Micro-costing type evaluation of packaging of Intravitreal injections of Bevacizumab in pharmacy hospital. — 12 months; Quality of life coefficient: HUI 3 questionnaire — 12 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON